Volume | 281,046 |
|
|||||
News | - | ||||||
Day High | 5.49 | Low High |
|||||
Day Low | 5.13 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Capricor Therapeutics Inc | CAPR | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
5.14 | 5.13 | 5.49 | 5.15 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,251 | 281,046 | $ 5.34 | $ 1,499,674 | - | 2.68 - 8.2212 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
13:33:37 | 100 | $ 5.185 | USD |
Capricor Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
162.02M | 31.40M | - | 25.18M | -22.29M | -0.71 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Capricor Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CAPR Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 5.00 | 5.6463 | 4.70 | 5.00 | 499,434 | 0.185 | 3.70% |
1 Month | 6.79 | 7.28 | 4.685 | 5.70 | 369,047 | -1.61 | -23.64% |
3 Months | 4.04 | 7.28 | 3.56 | 5.60 | 323,114 | 1.15 | 28.34% |
6 Months | 2.76 | 7.28 | 2.68 | 4.85 | 276,492 | 2.43 | 87.86% |
1 Year | 3.93 | 8.2212 | 2.68 | 4.74 | 217,368 | 1.26 | 31.93% |
3 Years | 3.92 | 8.2212 | 2.56 | 4.57 | 266,483 | 1.27 | 32.27% |
5 Years | 0.495 | 12.32 | 0.2526 | 5.92 | 757,173 | 4.69 | 947.47% |
Capricor Therapeutics Description
Capricor Therapeutics, Inc. is a San Diego based biotechnology company focused on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of muscular and other select diseases. Capricor's lead candidate, CAP-1002, is an allogeneic cardiac-derived cell therapy that is currently in late-stage clinical development for treating Duchenne muscular dystrophy (DMD). Capricor is also developing its exosome technology as a next-generation therapeutic platform. Capricor's proprietary StealthX¿ exosome platform has potential for a broad range of new therapeutic applications in the field of vaccinology as well as targeted oligonucleotide, protein and small molecule therapeutics to treat or prevent a variety of diseases. |